

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Submission is to CORRECT AN ERROR made in a previously recorded document that erroneously affects the identified Applications/Patents.
CONVEYING PARTY DATA	
Name	Execution Date
Institute of Virology Slovak Academy of Sciences	07/04/2013
RECEIVING PARTY DATA	
Name:	Institute of Virology Slovak Academy of Sciences
Street Address:	Dubravska Cesta 9
City:	Bratislava
State/Country:	SLOVAKIA
Postal Code:	842 46
PROPERTY NUMBERS Total: 56	
Property Type	Number
Application Number:	07964589
Application Number:	08177093
Application Number:	08260190
Application Number:	08335469
Application Number:	08477504
Application Number:	08481658
Application Number:	08485049
Application Number:	08486756
Application Number:	08487077
Application Number:	09177776
Application Number:	09178115
Application Number:	09807949
Application Number:	09967237
Application Number:	10795933

OP \$2240.00 07964589

Application Number:	11166997
Application Number:	11448576
Application Number:	11706101
Application Number:	11726065
Application Number:	11927150
Application Number:	11929351
Application Number:	11929415
Application Number:	11929474
Application Number:	11929601
Application Number:	11929652
Application Number:	11929750
Application Number:	11929816
Application Number:	11930041
Application Number:	11932697
Application Number:	11932777
Application Number:	11932843
Application Number:	11932997
Application Number:	11933151
Application Number:	11933180
Application Number:	12396879
Application Number:	12543026
Application Number:	12850432
Application Number:	12900282
Application Number:	12972298
Application Number:	13364871
Application Number:	08485862
Application Number:	08485863
Application Number:	08787739
Application Number:	09772719
Application Number:	10723795
Application Number:	10888694
Application Number:	10921590
Application Number:	11222986
Application Number:	11356568
Application Number:	11578744

	11924587
Application Number:	11929774
Application Number:	11930055
Application Number:	11932944
Application Number:	11933065
Application Number:	11933101
Application Number:	12321506

<b>CORRESPONDENCE DATA</b>	
Fax Number:	
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	703-243-6333
Email:	mail@mwzb.com
Correspondent Name:	Millen, White, Zelano & Branigan (Mia)
Address Line 1:	2200 Clarendon Blvd.
Address Line 2:	Suite 1400
Address Line 4:	Arlington, VIRGINIA 22201

ATTORNEY DOCKET NUMBER:	BAYSLV-0001-X
NAME OF SUBMITTER:	Michaiah Copp
Signature:	/Michaiah Copp/
Date:	07/24/2013

<b>Total Attachments: 3</b> source=EXECUTED_DEC_RE_ERRONEOUS_ASSIGN#page1.tif source=EXECUTED_DEC_RE_ERRONEOUS_ASSIGN#page2.tif source=EXECUTED_DEC_RE_ERRONEOUS_ASSIGN#page3.tif	
--	--

## DECLARATION REGARDING ERRONEOUS DEED OF ASSIGNMENT

We, Jaromir Pastorek, DSc. and Silvia Pastorekova, DSc., are authorized representatives of the INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (hereinafter, "ASSIGNEE") of Dubravska Cesta 9, 842 46 Bratislava, SLOVAKIA. We are familiar with the rightful ownership of the patents and applications listed in Exhibit "A" attached hereto.

1. As representatives of ASSIGNEE, we state that ASSIGNEE is the correct and rightful assignee of the entire legal right, title and interest previously assigned by the respective inventors of all U.S. Letters Patent and/or U.S. Patent Applications listed in Exhibit "A" attached hereto, and the inventions covered thereby, the application(s) from which said Letters Patent issued and all U.S. and foreign and international treaty priority rights claimed therein or corresponding thereto as well as all continuation and divisional applications claiming benefit of any of said applications, with the exception of legal rights of co-inventors of certain of said patents and applications listed on Exhibit "A" who have not assigned their rights to the ASSIGNEE.

2. Due to an inadvertent clerical error in Assignment Recordation by Bayer Healthcare LLC of 555 White Plains Road, Tarrytown, New York 10591 ("BHC"), BHC erroneously filed a change of name Assignment against the applications and patents listed in Exhibit "A," said assignment recorded on July 27, 2009, at Reel/Frame: 023027 / 0804, from the purported Assignor, Bayer Pharmaceuticals Corporation ("BPC"), a licensee of the patents and applications listed on Exhibit "A," to the purported Assignee, BHC, which erroneous assignment was recorded against these applications and patents rightfully legally owned by the ASSIGNEE, and/or legally owned by co-inventors who never assigned to either the ASSIGNEE or BPC.

3. The clerical error that was made was recordation of the mass change of name Assignment from purported Assignor BPC to the purported Assignee BHC against patents and patent applications that were not assigned to BPC, which error is clear from the assignment record, and which error resulted from information about licensed patents and applications listed in BHC's docketing system being erroneously and unintentionally listed on the mass assignment and submitted for recordation.


4. The INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES was, is and remains the rightful ASSIGNEE of the entire legal right, title and interest previously assigned by the respective inventors of all U.S. Letters Patent and/or U.S. Patent Applications listed in Exhibit "A" and attached hereto, and the inventions covered thereby, the application(s) from which said Letters Patent issued and all U.S. and foreign and international treaty priority rights claimed therein or corresponding

thereto as well as all continuation and divisional applications claiming benefit of any of said applications, with the exception of legal rights of co-inventors of certain of said patents and applications listed on Exhibit "A" who have not assigned their rights to the ASSIGNEE.

5. The true and rightful ASSIGNEE, the INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES, confirms that the chain of title of each of the patents and applications identified in the attached Exhibit "A" should not be considered altered by the incorrect assignment/name change from BPC to BHC, and is in all cases the last correct ASSIGNEE from the inventor(s), if any, that ASSIGNEE has been and continues to be, the owner of the patents and applications, with the exception of the legal rights of co-inventors of certain of said patents and applications listed on Exhibit "A" who have not assigned their rights to the ASSIGNEE; and that all assignments from BPC to BHC should be stricken from the chain of title of all of said patents and applications listed in Exhibit "A."

6. We further declare that all statements made herein of our own knowledge are true and all statements made on information and belief are believed to be true, and further that those statements were made with the knowledge that willful, false statements and the like are punishable by fine or imprisonment, or both under § 1001 of Title 18 of the United States Code, and such willful false statements may jeopardize the validity of any patents issued from the patent application.

Date: JULY 4, 2013


Signature: 

Name: Jaromir Pastorek, DSc.

Title: \_\_\_\_\_

INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES

Date: JULY 4, 2013

Signature: 

Name: Silvia Pastorekova, DSc.

Title: SENIOR SCIENTIST

INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES

**EXHIBIT "A"**

Application No.:	Filing Date:	Title of Invention:
07/964,589	Oct. 21, 1992	MN GENE AND PROTEIN
08/177,093	Dec. 30, 1993	MN-SPECIFIC ANTIBODIES AND THEIR USE IN CANCER TREATMENT
08/280,190	Jun. 15, 1994	MN GENE AND PROTEIN
08/335,469	Nov. 7, 1994	METHODS OF IMAGING NEOPLASTIC DISEASE AND OF DETECTING AND QUANTIFYING MN PROTEIN/POLYPEPTIDE USING MN-SPECIFIC ANTIBODIES
08/475,017	Nov. 7, 1994	MN GENE AND PROTEIN
08/477,504	Jun. 7, 1995	MN PROTEINS, POLYPEPTIDES, FUSION PROTEINS AND FUSION POLYPEPTIDES
08/481,656	Jun. 7, 1995	METHOD OF INHIBITING TUMOR GROWTH USING ANTIBODIES TO MN PROTEIN
08/485,049	Jun. 7, 1995	MN GENE AND PROTEIN
08/485,756	Jun. 7, 1995	MN-SPECIFIC ANTIBODIES AND HYBRIDOMAS
08/487,077	Jun. 7, 1995	MN GENE AND PROTEIN
09/177,776	Oct. 23, 1998	MN GENE AND PROTEIN
09/178,115	Oct. 23, 1998	MN GENE AND PROTEIN
09/807,949	Oct. 22, 1999	MN GENE AND PROTEIN
09/867,237	Sept. 27, 2001	ANTI-IDIOTYPE ANTIBODIES TO MN PROTEINS AND MN POLYPEPTIDES
10/319,003	Dec. 13, 2002	MN GENE AND PROTEIN
10/795,933	Mar. 8, 2004	MN GENE AND PROTEIN
11/166,997	Jun. 24, 2005	MN and hypoxia
11/448,576	Jun. 7, 2006	ANTI-ANTI-IDIOTYPE ANTIBODIES TO MN PROTEINS AND MN POLYPEPTIDES
11/706,101	Feb. 13, 2007	MN GENE AND PROTEIN
11/726,065	Mar. 20, 2007	MN/CA IX and MAPK inhibition
11/927,150	Oct. 28, 2007	MN/CA IX AND EGFR PATHWAY INHIBITION
11/929,361	Oct. 30, 2007	MN GENE AND PROTEIN
11/929,415	Oct. 30, 2007	MN GENE AND PROTEIN
11/929,474	Oct. 30, 2007	MN GENE AND PROTEIN
11/929,601	Oct. 30, 2007	CA IX-SPECIFIC INHIBITORS
11/929,652	Oct. 30, 2007	CA IX-SPECIFIC INHIBITORS
11/929,750	Oct. 30, 2007	CA IX-Specific Inhibitors
11/929,816	Oct. 30, 2007	CA IX-SPECIFIC INHIBITORS
11/930,041	Oct. 30, 2007	MN GENE AND PROTEIN
11/932,697	Oct. 31, 2007	MN GENE AND PROTEIN
11/932,777	Oct. 31, 2007	Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IX's Coexpression with Her-2/neu/c-erbB-2, and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes
11/932,843	Oct. 31, 2007	MN GENE AND PROTEIN
11/932,897	Oct. 31, 2007	MN GENE AND PROTEIN
11/933,151	Oct. 31, 2007	MN GENE AND PROTEIN
11/933,180	Oct. 31, 2007	MN GENE AND PROTEIN
12/386,879	Mar. 3, 2009	MN and Hypoxia
12/444,888	Oct. 12, 2007	MN/CA9 Splice Variants
12/543,026	Aug. 18, 2009	MN GENE AND PROTEIN
12/850,432	Aug. 4, 2010	MN GENE AND PROTEIN
12/900,282	Oct. 7, 2010	MN/CA IX and EGFR Pathway Inhibition
12/972,298	Dec. 17, 2010	MN GENE AND PROTEIN
13/364,871	Feb. 2, 2012	MN/CA IX AND EGFR PATHWAY INHIBITION
08/485,862	Jun. 7, 1995	IMMUNOLOGICAL METHODS OF DETECTING MN PROTEINS AND MN POLYPEPTIDES
08/485,883	Jun. 7, 1995	DETECTION AND QUANTITATION OF MN SPECIFIC ANTIBODIES
08/787,739	Jan. 24, 1997	MN GENE AND PROTEIN
09/772,719	Jan. 30, 2001	MN GENE AND PROTEIN
10/575,300	Oct. 18, 2004	MN/CA IX AND CANCER PROGNOSIS
10/723,795	Nov. 26, 2003	CA IX-SPECIFIC INHIBITORS
10/888,694	Jul. 8, 2004	MN GENE AND PROTEIN
10/921,590	Aug. 19, 2004	SOLUBLE FORM OF CARBONIC ANHYDRASE IX (S-CA IX), ASSAYS TO DETECT S-CA IX, CA IX'S COEXPRESSION WITH HER-2/NEU/C-ERBB-2, AND CA IX-SPECIFIC MONOCLONAL ANTIBODIES TO NON-IMMUNODOMINANT EPITOPES
11/222,986	Sept. 8, 2005	CA IX-SPECIFIC INHIBITORS
11/356,568	Feb. 17, 2006	MN GENE AND PROTEIN
11/578,744	May. 4, 2005	MN/CA IX/CA9 AND RENAL CANCER PROGNOSIS
11/924,587	Oct. 25, 2007	CA IX-SPECIFIC INHIBITORS
11/929,536	Oct. 30, 2007	CA IX-SPECIFIC INHIBITORS
11/929,774	Oct. 30, 2007	CA IX-SPECIFIC INHIBITORS
11/930,055	Oct. 30, 2007	MN GENE AND PROTEIN
11/932,944	Oct. 31, 2007	MN GENE AND PROTEIN
11/933,065	Oct. 31, 2007	SOLUBLE FORM OF CARBONIC ANHYDRASE IX (S-CA IX), ASSAYS TO DETECT S-CA IX, CA IX'S COEXPRESSION WITH HER-2/NEU/C-ERBB-2, AND CA IX-SPECIFIC MONOCLONAL ANTIBODIES TO NON-IMMUNODOMINANT EPITOPES
11/933,101	Oct. 31, 2007	SOLUBLE FORM OF CARBONIC ANHYDRASE IX (S-CA IX), ASSAYS TO DETECT S-CA IX, CA IX'S COEXPRESSION WITH HER-2/NEU/C-ERBB-2, AND CA IX-SPECIFIC MONOCLONAL ANTIBODIES TO NON-IMMUNODOMINANT EPITOPES
12/181,951	Jul. 29, 2008	MN/CA IX AND BREAST CANCER THERAPY
12/321,506	Jan. 22, 2009	MN/CA IX/CA9 AND RENAL CANCER PROGNOSIS
12/371,861	Feb. 16, 2009	MN/CA IX AND CANCER PROGNOSIS
12/444,888	Oct. 12, 2007	MN/CA9 Splice Variants
12/774,158	May. 5, 2010	MN/CA IX AND CANCER PROGNOSIS